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Podocyte foot process effacement is characteristic of
proteinuric renal diseases. In minimal change nephrotic
syndrome (MCNS) foot processes are diffusely effaced
whereas the extent of effacement varies in focal segmental
glomerulosclerosis (FSGS). Here we measured foot process
effacement in FSGS and compared it to that in MCNS and in
normal kidneys. A clinical diagnosis was used to differentiate
idiopathic FSGS from secondary FSGS. Median foot process
width, determined morphometrically by electron microscopy,
was 3236 nm in 17 patients with idiopathic FSGS, 1098 nm in
7 patients with secondary FSGS, and 1725 nm in 15 patients
with MCNS, as compared to 562 nm in 12 control patients.
Multivariate analysis showed that foot process width did not
correlate with proteinuria or serum albumin levels but was
significantly associated as an independent factor with the
type of disease. Foot process width over 1500 nm
differentiated idiopathic from secondary FSGS with high
sensitivity and specificity. Our results show that quantitative
analysis of foot processes may offer a potential tool to
distinguish idiopathic from secondary FSGS.
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Podocyte foot process effacement is an invariable feature of
proteinuric glomerular diseases such as focal segmental
glomerulosclerosis (FSGS), minimal change disease, immuno-
globulin (Ig) A nephropathy, and diabetic nephropathy.1–3
Few studies have assessed foot process effacement in a
quantitative way. It was suggested that the degree of foot
process effacement might depend on the underlying disease.
In patients with minimal change nephrotic syndrome
(MCNS), foot process effacement estimated by foot process
width (FPW), was more extensive than in patients with
proteinuric IgA nephropathy.2 The degree of foot process
effacement appeared to be independent of the level of
proteinuria, suggesting that the extent of foot process
effacement is determined by the nature of podocyte injury.2
Podocyte damage in idiopathic MCNS and idiopathic FSGS
has been linked to a putative glomerular permeability factor,
which would suggest that the extent of podocyte damage is
similar in the two disorders.4–6 Especially in patients
presenting with the tip variant of FSGS, the extent of foot
process effacement may be similar to MCNS, as these patients
often have presenting features and outcome that more closely
resembles MCNS.7,8 Alternatively, the group of Kerjaschki
demonstrated that the expression of dystroglycan, an
adhesion molecule between the podocyte and the glomerular
basement membrane (GBM), is significantly lower in MCNS
compared to FSGS, suggesting that the mechanism of foot
process fusion may differ in MCNS and FSGS.9
To our knowledge the degree of foot process fusion in
FSGS and FSGS variants has never been compared to that in
MCNS. We are aware of a limited number of semiquantitative
studies on podocyte alterations in patients with idiopathic
and secondary forms of FSGS.10,11 These studies showed that
the mean percentage of the glomerular surface area affected
by foot process fusion was less in patients with FSGS
secondary to maladaptive structural–functional responses
compared to idiopathic FSGS. However, there was a
considerable degree of overlap. The semiquantitative method
used in these studies in FSGS precludes a direct comparison
with the quantitative method used to assess the degree of foot
process effacement in patients with MCNS.2 In the present
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study, we have performed a morphometric analysis of
podocyte foot processes in patients diagnosed with idiopathic
FSGS and FSGS secondary to maladaptive responses. The
degree of foot process effacement in FSGS and FSGS variants
was compared to the degree of foot process effacement in
MCNS and normal kidneys.
RESULTS
Baseline characteristics of adult patients with FSGS are shown
in Table 1. By clinical criteria, idiopathic FSGS was diagnosed
in 17 patients and FSGS secondary to maladaptive responses
was diagnosed in 12 patients. A secondary cause was
identified in seven patients: reflux nephropathy (n¼ 2),
atrophic kidney (n¼ 2), unilateral agenesis of the kidney
(n¼ 1), nephrectomy after hydronephrosis (n¼ 1), and
obesity (n¼ 1; BMI of 33.2 kg/m2). Five patients had
nephrotic range proteinuria with a normal serum albumin,
compatible with a diagnosis of FSGS secondary to maladap-
tive responses.12 The baseline characteristics of these five
patients were not different from patients with an identifiable
secondary cause (Table 1). However, we cannot exclude
idiopathic FSGS in these patients with absolute certainty.
Therefore, to generate unbiased data, results of these patients
with possible secondary FSGS are reported but not included
in the statistical analysis.
Four patients with idiopathic FSGS and two patients with
secondary FSGS were treated with an ACE inhibitor (ACEi)
at the time of renal biopsy. Perihilar FSGS was more common
in patients diagnosed with secondary FSGS, whereas the tip
lesion was seen more often in idiopathic FSGS (Table 1). As
expected proteinuria and serum cholesterol were lower in
patients with secondary FSGS. These patients also had a
higher serum creatinine concentration compared to idio-
pathic FSGS. This is probably related to the more indolent
course of FSGS secondary to maladaptive responses. As a
consequence a renal biopsy is often not performed until renal
function deteriorates. Another reason for the higher serum
creatinine in patients with secondary FSGS may be that many
have a loss of functioning nephrons as a stimulus for the
maladaptive response.
Eight patients with idiopathic FSGS, one patient with
secondary FSGS and one patients with possible secondary
FSGS received immunosuppressive therapy with prednisone
(n¼ 4) or prednisone and cyclophosphamide/cyclosporine
(n¼ 6) after renal biopsy. Remission rate at 5 years was
significantly higher in patients with idiopathic FSGS (87%)
compared to patients with secondary FSGS (14%; Po0.01).
Remission rate at 5 years was 0% in patients with possible
secondary FSGS.
Patients with MCNS presented with a mean proteinuria of
9.2±4.1 g per day and a mean serum albumin of 21±5 g/l
(P¼NS and Po0.05, respectively, for the difference with
FSGS). Mean age at biopsy was 38±19 years (Po0.01 for the
difference with FSGS). A renal biopsy was performed within
1 month after presentation in 63% of patients with MCNS.
Use of ACEi at the time of biopsy in these patients was not
recorded; however, such therapy was unlikely to be started in
patients with a sudden onset of a nephrotic syndrome. The
controls had no proteinuria with a mean serum albumin of
39±7 g/l. Mean age at biopsy was 51±16 years.
Morphometric analysis and determinants of foot process
width
Median FPW was 2290 nm (range, 626–8632 nm) in patients
with FSGS irrespective of the underlying cause (idiopathic or
secondary) and 1725 nm (range, 1216–2685 nm) in MCNS
(Figure 1; Po0.05). FPW in normal kidneys was significantly
lower compared to FSGS and MCNS with a median FPW of
562 nm (range, 508–827 nm; Po0.001).
Foot process width correlated with type of disease
(MCNS, idiopathic or secondary FSGS; r¼ 0.61; Po0.001).
FPW also correlated with age at biopsy (r¼ 0.39; Po0.05),
Table 1 | Characteristics of patients with FSGS at biopsy
FSGS secondary to maladaptive responses (n=12)
Idiopathic FSGS
(n=17)
With identifiable secondary
cause (n=7)
Without identifiable secondary
cause (possible secondary FSGS; n=5)a P-value
Sex (M/F) 12/5 4/3 3/2 0.68
Age at biopsy (years) 52±13 54±14 45±15 0.57
Serum creatinine (mmol/l) 112±56 262±18 162±88 o0.01
Serum albumin (g/l) 21±5 37±5 41±3 o0.001
Proteinuria (g per day) 9.4±3.8 5.0±1.8 4.5±0.9 o0.01
Serum cholesterol 11.1±2.3 6.8±1.4 5.8±1.3 o0.01
Mean arterial blood pressure (mm Hg) 110±14 120±17 104±17 0.21
Hypertension (%) 72% 86% 80% 0.28
Presentation to biopsy (months) 2.4 (0.5–16.1) 63.7 (0.3–135) 120 (60.1–477) 0.01
FSGS variant o0.01
NOS 6 2 0
Tip 9 0 0
Perihilar 1 5 5
Collapsing 1 0 0
FSGS, focal segmental glomerulosclerosis; F, female; M, male; NOS, not otherwise specified.
aThese patients were not included in the statistical analysis.
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but not with serum albumin (r¼0.13; P¼NS), serum
creatinine (r¼0.15; P¼NS), treatment with ACEi
(r¼0.11; P¼NS; n¼ 24) or proteinuria (r¼ 0.24; P¼NS;
Figure 2). On multivariate analysis, type of disease (MCNS,
idiopathic or secondary FSGS) was the only determinant of
FPW (Po0.001).
We further analyzed the differences in FPW between
idiopathic and secondary FSGS in comparison with MCNS
(Figure 3). Foot process effacement was most severe in
idiopathic FSGS and intermediate in MCNS, as reflected by a
FPW of 3236 nm (range, 1606–8632 nm) and 1725 nm (range,
1216–2685 nm) respectively (P¼ 0.001 for idiopathic FSGS vs
MCNS). Foot processes were relatively preserved in FSGS
secondary to maladaptive responses, with a FPW of 1098 nm
(range, 626–1800 nm). Statistical significance was Po0.001
for idiopathic vs secondary FSGS and P¼ 0.001 for MCNS vs
secondary FSGS. FPW in patients with possible secondary
FSGS was 701 nm (range, 664–1258 nm).
The degree of overlap in FPW between idiopathic and
secondary FSGS was low. Patients with idiopathic FSGS were
characterized by a FPW above 1500 nm (Table 2). Receiver
operating characteristics curve analysis showed that this
cutoff value differentiated patients with idiopathic FSGS
from secondary FSGS with a high sensitivity (100%) and
specificity (72%). The degree of overlap between MCNS and
idiopathic or secondary FSGS was high, and FPW could not
accurately differentiate between these diseases.
Foot process width and FSGS variants
Including both patients with idiopathic and secondary FSGS,
the degree of foot process effacement was not significantly
different between FSGS variants (Figure 4). Median FPW was
3848 nm (range, 957–8631 nm) for FSGS not otherwise
specified (NOS), 2551 nm (range, 1606–4414 nm) for the
tip variant and 1570 nm (range, 626–6486 nm) for perihilar
FSGS. FPW was significantly lower in patients with MCNS
(1725 nm; range, 1217–2685 nm) compared to patients with
the tip variant (Po0.05).
On multivariate analysis, type of disease (idiopathic or
secondary FSGS) but not FSGS variant was the only
determinant of FPW in patients with FSGS. Within the
group of patients with idiopathic FSGS, the degree of foot
process effacement was most severe in FSGS NOS (5015 nm;
range, 1875–8632 nm), intermediate in the tip variant
(2551 nm; range, 1606–4414 nm), and least severe in MCNS
(1725 nm; range, 1217–2685 nm). The differences in foot
process effacement were statistically significant, with Po0.05
for FSGS NOS vs FSGS tip variant, P¼ 0.001 for FSGS NOS
vs MCNS, and Po0.05 for FSGS tip variant vs MCNS.
DISCUSSION
Podocyte foot process effacement is present in most
proteinuric diseases, such as MCNS, FSGS, membranous
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Figure 1 | Median foot process width with 95% confidence
interval in patients with FSGS, minimal change nephrotic
syndrome and controls.
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Figure 2 | Proteinuria versus foot process width in the
individual patients with idiopathic FSGS (m), minimal change
nephrotic syndrome (K), FSGS secondary to maladaptive
responses (n) and possible secondary FSGS (,*). * These
patients were not included in the statistical analysis.
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Figure 3 | Foot process width of patients with idiopathic FSGS
(m), minimal change nephrotic syndrome (MCNS; K), FSGS
secondary to maladaptive responses (n), or possible
secondary FSGS (,*). Median foot process width is indicated by
horizontal line. *These patients were not included in the statistical
analysis.
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nephropathy, and IgA nephropathy. It is considered to be a
stereotypical reaction of podocytes to injury or damage. The
exact mechanism resulting in foot process effacement
remains unknown.13,14 Our current study confirms previous
findings suggesting that the degree of foot process effacement
is primarily dependent on the nature of the underlying
disease and not a consequence of proteinuria.2 In multi-
variate analysis, type of disease was the only determinant of
FPW. This finding correlates with more recent insights into
podocyte biology, indicating that both proteinuria and
morphological alterations in podocytes or slit pores are
consequences of podocyte injury.13,15,16 In an experimental
model of acutely induced proteinuria, we observed wide-
spread effacement of foot processes before the onset of
proteinuria.16 Also from human studies, there is evidence
that proteinuria and podocyte alterations are not necessarily
interdependent.17 We have previously described a familial
nephropathy, characterized by marked long-standing protei-
nuria but with normal podocytic foot processes.18 These
observations strengthen our conclusion that it is the type of
disease (MCNS, idiopathic, or secondary FSGS), rather than
the amount of proteinuria that determines foot process
effacement.
Admittedly, counting of the foot processes and the
necessary assessment of the distinctive separations between
individual foot processes can be somewhat subjective as
illustrated by Figures 5–8. However, in our study this had no
major impact on the conclusions of the paper. First, in
495% of all counted separations the decision was unambig-
uous; second, counting was performed in a blinded fashion,
without awareness of patients characteristics; third, adding
the debatable separations would have increased the absolute
number of foot processes by a few percent, however, without
affecting the differences between the groups.
In our patient group, FPW also correlated with age, due to
a significant lower age in patients with MCNS compared to
patients with FSGS. However, it seems unlikely that the
difference in age explains the difference in FPW. On
multivariate analysis type of disease, not age, was the only
determinant of FPW. Furthermore, there was also no
correlation between FPW and age in our control patients
(data not shown). If age is an important determinant, FPW
should have increased with age in these patients with ages
ranging from 30 to 70 years.
Table 2 | Predicting disease type by foot process width or disease type
Idiopathic FSGS (n=17)
FSGS secondary to
maladaptive responses (n=7) MCNS (n=15) P-value
Foot process width o0.001
41500 nm 17 2 10
o1500 nm 0 5 5
FSGS, focal segmental glomerulosclerosis; MCNS, minimal change nephrotic syndrome.
Po0.001 for difference between idiopathic FSGS and FSGS secondary to maladaptive responses.
P=not significant for difference between MCNS and FSGS secondary to maladaptive responses.
Po0.001 for difference between idiopathic FSGS and MCNS.
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Figure 4 | Foot process width of patients with FSGS NOS, FSGS
tip variant, perihilar FSGS, or minimal change nephrotic
syndrome (MCNS). Median foot process width is indicated by
horizontal line. m¼ idiopathic FSGS, n¼ FSGS secondary to
maladaptive responses, ,*¼possible secondary FSGS,
K¼MCNS. *These patients were not included in the statistical
analysis.
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Figure 5 | Electron microscopic photographs to illustrate the
difference between separate foot processes and foot process
fusion. (a) Example of two separate foot processes. The lateral
membranes of the foot processes, indicated by white dotted lines, are
identifiable over the entire length from the apical side to the
glomerular basement membrane (GBM). CL; capillary lumen.
(b) Example of fused foot processes. The lateral membranes (white
dotted lines) merge near the glomerular basement membrane (GBM)
and are not identifiable over the entire length. CL; capillary lumen.
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The expression of angiotensin II receptors in podocytes
has been associated with the development of FSGS and could
affect FPW through foot process contractility and cyto-
skeleton dynamics.19 Therefore, treatment with an ACEi may
reduce the extent of foot process effacement. In our study,
only a small number of patients with FSGS were treated with
ACEi at the time of renal biopsy and treatment showed no
correlation with FPW. Admittedly, data on ACEi use in
patients with MCNS were not available. However, even the
highest possible correlation between ACEi use and FPW in
patients with MCNS would not have changed the results
(data not shown). Type of disease still remained the only
determinant of FPW.
Over the last years several causes of podocyte injury have
been identified that can lead to foot process effacement.15
Important causes are interference with structural compo-
nents of the slit diaphragm complex and its lipid rafts, direct
interference with the actin-cytoskeleton and interference with
podocyte–GBM interaction.20 In addition, at least in some
patients with idiopathic FSGS and MCNS there is evidence
that podocyte injury is the direct result of a circulating
factor.4–6 Thusfar identification of this factor has been
unsuccessful. The difference in foot process effacement in
idiopathic FSGS and MCNS in our study suggests that the
underlying cause of podocyte injury differs between the two
disorders. This is in agreement with the notion that different
plasma factors appear to be involved in idiopathic FSGS and
MCNS.21
Admittedly, the difference may not be associated with the
underlying cause, but merely represent a difference in time to
biopsy. Patients with MCNS were biopsied earlier after onset
of proteinuria and foot process effacement may not have
reached the maximum extent. To our knowledge there are no
studies in humans showing a correlation between time of
biopsy and the extent of foot process effacement in MCNS.
Some data are available from animal studies. A Japanese
group developed an animal model similar to MCNS.
Injection of monoclonal antibody 5-1-6, an antigen directed
at the extracellular domain of the rat homolog of nephrin,
causes massive proteinuria without histologic abnormalities
on light microscopy.22 Even after repeated doses, light
microscopy showed minimal glomerular lesions.23 At 8 days
after injection of monoclonal antibody 5-1-6 partial retrac-
tion of foot processes was seen on electron microscopic
examination.22 In this model, proteinuria preceded the
effacement of foot processes. Thus, if a biopsy is performed
shortly after the onset of proteinuria foot process effacement
may be less severe. However, it is questionable whether this
model applies to humans with MCNS. Even after repeated
doses for 25 weeks, only partial foot process effacement was
found. This is clearly different from humans with MCNS,
who show complete foot process effacement on renal biopsy.
The difference in time interval is notable. Our results do
not exclude a single underlying cause of podocyte injury in
idiopathic FSGS and MCNS. In patients with MCNS,
idiopathic FSGS tip variant and idiopathic FSGS NOS, we
observed a gradual, but significant, increase in the severity of
foot process effacement. This finding could also indicate that
idiopathic FSGS variants and MCNS reflect different stages of
the same underlying disease. Injury to the podocytes results
in foot process effacement and proteinuria, initially without
light microscopic lesions (MCNS). As the disease progresses,
podocytic foot processes become more effaced and light
microscopic lesions appear, first the tip variant and as
damage to the foot processes continues, sclerotic lesions
(FSGS NOS) develop. This concept is supported by recent
data from the literature. Howie et al.24 reported on patients
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Figure 6 | Representative electron microscopic image of a
glomerulus from a patient with idiopathic FSGS. The
separations between the foot processes have been marked with
arrows in the detailed images a–e. CL; capillary lumen; GBM;
glomerular basement membrane.
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with an initial diagnosis of MCNS. Tip lesions developed in
subsequent biopsies from these patients. In one patient, tip
lesions progressed to FSGS NOS lesions. We observed a
similar pattern in a transplant kidney from a patient with
recurrent FSGS after renal transplantation (Smeets et al.
Morphological variants of FSGS reflect differences in
developmental stage of the lesion. J Am Soc Nephrol
18:216A, 2007).25 Some glomeruli only showed FSGS tip
variant, whereas FSGS NOS was present in other glomeruli,
suggesting that a single cause can result in different FSGS
variants. Obviously, FSGS and MCNS are complex diseases
that are manifestations of many underlying causes and this
sequence of events will not apply to all patients with FSGS or
MCNS.7,24
It is unlikely that inclusion of patients with genetic
mutations in GBM or podocyte proteins (dystroglycans,
nephrin, podocin, a-actinin-4) contributed to the difference
in foot process effacement.9,13,15,26 Familial forms were
excluded after examination of the patient charts. Sporadic
genetic mutations are also unlikely, as these mutations are
rare in adult patients and if present they are characterized by
therapy resistance.27–29
Foot processes in patients with FSGS secondary to
maladaptive responses were more conserved than in
a b d
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Figure 7 | Representative electron microscopic image of a glomerulus from a patient with FSGS secondary to maladaptive
responses. The separations between the foot processes have been marked with arrows in the detailed images (a–d). CL; capillary lumen,
GBM; glomerular basement membrane.
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Figure 8 | Representative electron microscopic image of a glomerulus from a patient with minimal change nephrotic syndrome. The
separations between the foot processes have been marked with arrows in the detailed images (a–f). CL; capillary lumen, GBM; glomerular
basement membrane.
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idiopathic FSGS and MCNS. In fact, the difference in foot
process effacement with idiopathic FSGS was large enough
to define a cutoff value for FPW that can predict idiopathic
or secondary FSGS with a high sensitivity and specificity.
Our results are in agreement with studies in a specific
group of patients with secondary FSGS due to obesity.10,30
These latter studies demonstrated that obesity-related
FSGS was characterized by relatively mild foot process
fusion, indicating that idiopathic FSGS and FSGS secondary
to maladaptive responses can be distinguished by different
morphologic features. Admittedly measurement of FPW is
quite laborious. To reach the discriminative threshold of
1500 nm, we needed to count an average of 2.6 and 3.8
glomeruli for patients with idiopathic and secondary
FSGS, respectively. However, less time consuming techniques
are not reliable. In agreement with data from D’Agati11,
estimation of the mean percentage of the glomerular surface
area affected by foot process fusion did not allow us to
differentiate between idiopathic and secondary FSGS
(data not shown). Similarly, a manual count of the number
of foot processes per individual capillary loop, without
measurement of the GBM, was far less predictive compared
to measurement of FPW. Alternatively, clinical parameters
such as serum albumin are often sufficient to distinguish
between idiopathic FSGS and FSGS secondary to maladaptive
responses. In a study of 37 patients with nephrotic range
proteinuria due to biopsy proven FSGS, Praga et al.12,31
showed that serum albumin was significantly lower in
patients with presumed idiopathic FSGS (serum albumin
o30 g/l) compared to FSGS secondary to maladaptive
responses (serum albumin 435 g/l). However, in patients
with a serum albumin between 30 and 35 g/l without an
apparent secondary cause, the distinction between idiopathic
and secondary forms of FSGS often poses a challenge to the
nephrologist caring for patients with FSGS.32 In these
patients, foot process measurement could be helpful in
guiding diagnosis and prevent inappropriate treatment with
steroids and cytotoxic agents that are not effective in
secondary forms of FSGS.33 Our study did not include
patients with a serum albumin between 30 and 35 g/l without
a secondary cause, therefore future studies in this patient
group are needed to determine whether morphometric
analysis of podocytic foot processes can guide diagnosis
and treatment of FSGS.
In conclusion, our study demonstrates that FPW corre-
lates very well with idiopathic FSGS, MCNS, and FSGS
secondary to maladaptive responses, independent of the
degree of proteinuria. Foot processes are more effaced in
idiopathic FSGS NOS and FSGS tip variant than in MCNS.
Most severe foot process effacement is found in patients with
idiopathic FSGS NOS. These findings suggest that some
forms of idiopathic FSGS and MCNS may have a single
underlying cause. Additional studies are necessary to test this
hypothesis. In selected cases measurement of FPW can be
useful to distinguish between idiopathic FSGS and FSGS
secondary to maladaptive responses.
MATERIALS AND METHODS
Patients and controls
In total, 24 patients with biopsy proven FSGS were included in the
study. Light microscopic assessment of glomeruli for FSGS lesions
was performed in accordance with the Columbia classification
system described by D’Agati et al.34 This classification defines five
light microscopic patterns of FSGS: FSGS not otherwise specified
(NOS), perihilar variant, cellular variant, tip variant, and collapsing
variant. Adult patients with one of the above light microscopic
variants of FSGS and either negative immunofluorescence or only
segmental IgM and/or C3 were considered for the study.
For comparison we have used renal biopsy material of patients
with MCNS and control patients. Data on FPW of 12 patients with
MCNS and six patients after renal transplantation (used as control)
were available from a previous study.2 We have added three
additional patients with MCNS and six control renal tissues,
consisting of the apparently unaffected part of kidneys removed
because of a malignancy.
Light microscopy and electron microscopy
For light microscopy pieces of kidneys were fixed in Bouin’s solution
overnight at room temperature, dehydrated, and embedded in
paraplast (Amstelstad, Amsterdam, Netherlands). Thick sections
(Two mm) were stained with periodic acid Schiff and methenamine
silver.
For electron microscopy, small pieces of kidneys were fixed in
2.5% glutaraldehyde dissolved in 0.1 M sodium cacodylate buffer
(pH 7.4) overnight at 4 1C and washed in the same buffer. The tissue
fragments were postfixed in cacodylate-buffered 1% OsO4 for 2 h,
dehydrated, and embedded in Epon 812 (Merck, Darmstadt,
Germany). Ultrathin sections were cut on an ultratome (Leica,
Reichert Ultracuts, Wien, Austria), and contrasted with 4% uranyl
acetate for 45 min and subsequently with lead citrate for 4 min at
room temperature. Sections were examined in a Jeol 1200 EX2
electron microscope (JEOL, Tokyo, Japan).
Immunofluorescence microscopy
For immunofluorescence, kidney fragments were snap frozen in
liquid nitrogen, and 2 mm cryostat sections were incubated with
fluorescein-labeled antisera directed to human IgG, IgM, IgA, C1q,
C3, k, l and fibrinogen. The sections were examined with a
fluorescence microscope (Leica microsystems GmbH, Heidelberg,
Germany).
Measurements of foot processes and glomerular basement
membrane
Negatives of electron micrographs (magnification  6000) were
scanned at 600 d.p.i. resolution using a flatbed scanner (Epson
Perfection 1200 Photo, Epson Europe, Amsterdam), resulting in a
specimen-level pixel size of B7 7 nm2. Measurement of the
resulting images was performed using Zeiss KS400 (Carl Zeiss
Imaging Systems, Germany). The system was calibrated using the
marker bar on the electron micrographs. The magnification data
were verified by a grating replica with parallel lines (2160 lines/mm;
EMS, Washington, USA). For five open random capillary loops in
each of five randomly selected glomeruli per specimen, the GBM
was indicated interactively using a graphic tablet. The total
circumference of the capillary loop was included in the image in
475% of cases. Only the free filtering surface of the capillary loop
was studied. The image analysis software was used to measure the
length of the GBM for each loop. Also, for each loop the number of
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podocytic foot processes was manually counted and expressed as the
number of foot processes per mm GBM length, resulting in 25
measurement points for each specimen. A foot process was defined
as any connected epithelial segment butting on the basement
membrane, separated from the cytoplasmic extensions of the
adjacent foot processes by lateral membranes. A new foot process
was counted only if the lateral membranes of both foot processes
were clearly identifiable over the entire length, that is, from the
apical side till the attachment on the GBM (Figure 5). The presence
of a clear slit, with or without a diaphragm was thus not a
prerequisite.
To illustrate how the foot processes were counted, representative
electron microscopic images of the three main study groups
(idiopathic FSGS, FSGS secondary to maladaptive responses, and
MCNS) are shown in Figures 6–8. The separations between the foot
processes are marked with arrows.
For each patient, the average FPW was calculated by dividing the
total number of foot processes by the total length of the GBM. A
correction factor of p/4 was used to correct for presumed random
variation in the angle of the section relative to the long axis of the
podocyte.35,36 The measurements were performed without knowl-
edge of the clinical data. As indicated above, we have used data of 18
patients that were previously reported.2 To evaluate the influence of
interobserver variation and differences in equipment, we have
randomly measured 32 negatives of electron micrographs from these
patients. FPW measured by our method was 1584±740 nm fitting
very well with the results from the previous study, which measured a
FPW of 1432±805 nm (P¼NS). The correlation between the results
obtained in both centers was high (r¼ 0.97; Po0.001), although
there was a systematic bias, measurements in our center (RUNMC)
being 11% (confidence interval: 6–16%) lower.
Clinical data
Medical records were reviewed for clinical and laboratory data at
renal biopsy. Data collected were: age, sex, blood pressure, level of
protein excretion, serum creatinine, serum albumin, serum
cholesterol, use of immunosuppressive therapy, and antihyper-
tensive medication, initiation of dialysis and death. In addition, the
medical records were reviewed for diseases associated with
secondary FSGS: obesity (BMI430 kg/m2), renal atrophy, unilateral
renal agenesis, reflux nephropathy, infections (human immunode-
ficiency virus, parvovirus B19), medication (pamidronate, lithium,
interferon-a), intravenous drug abuse, family history of renal
disease, sickle cell anemia, or malignancies.30,34
Definitions
Presentation was defined as the time when proteinuria was first
detected. Nephrotic syndrome was defined as proteinuria of X3 g
per day in association with serum albumin concentration of
p30 g/l. Patients treated with antihypertensive drugs or with a
blood pressure 4140/90 mm Hg were considered hypertensive. A
complete remission was defined as proteinuria o0.3 g per 24 h with
a stable serum creatinine concentration (o50% increase from
baseline) and a partial remission was defined as proteinuria between
0.3 and 2.0 g per 24 h with X50% reduction in proteinuria from
baseline and a stable serum creatinine concentration.
Idiopathic FSGS was defined as a serum albumin p30 g/l in two
measurements in the 3-month period before and after renal biopsy,
with a normal renal size and anatomy (observed by intravenous
urogram or renal ultrasound), a body mass index o30 kg/m2 and
no other discernible cause of FSGS.1 A clinical diagnosis of FSGS
secondary to maladaptive responses was made in patients with an
identifiable cause and nephrotic range proteinuria (43 g per day)
with a serum albumin 435 g/l in two measurements in the 3-month
period before and after renal biopsy.12 A clinical diagnosis of
possible FSGS secondary to maladaptive responses was made in
patients without an identifiable cause and nephrotic range
proteinuria (43 g per day) with a serum albumin 435 g/l in two
measurements in the 3-month period before and after renal biopsy.
Statistical analysis
Values are given as means±s.d. or median (range) when appro-
priate. Differences in continuous data were analyzed with use of the
Wilcoxon summed rank test or Kruskal–Wallis test in case of more
than two groups. If the result of the Kruskal–Wallis test was
significant (Po0.05), then pairwise comparisons were performed
with the Wilcoxon rank-sum test. Fisher’s exact test was used for
categorical data. Spearman’s rank correlation coefficients were
calculated to assess the relation of FPW to age, proteinuria, serum
albumin, serum creatinine, use of ACEi/angiotensin receptor
blockers (all at biopsy), and disease type (MCNS, idiopathic or
secondary FSGS). Multiple regression analysis was performed in a
forward stepwise fashion to determine the relationship between
FPW and variables that were significant in univariate analysis, with
Po0.05 for inclusion of variables. As for strongly skewed variables
the high values may have a disproportionate influence on the
outcome of the analysis, the natural log transformation was used to
reduce their impact.
Receiver operating characteristics curves were used to determine
the most discriminative threshold for FPW in predicting MCNS,
idiopathic or secondary FSGS. A two-sided P-value o0.05 was
considered as the level of statistical significance. The analysis was
performed using SPSS 14.0 for windows (SPSS Inc., Cambridge,
MA, USA).
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